T2 Biosystems Inc
NASDAQ:TTOO
T2 Biosystems Inc
NASDAQ:TTOO
Price:
3.72 USD
1.92%
Market Closed
Updated:
May 4, 2024
Section:
Relative Value
The Relative Value of one
TTOO
stock under the Base Case scenario is
48.72
USD.
Compared to the current market price of 3.72 USD,
T2 Biosystems Inc
is
Undervalued by 92%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
TTOO
Relative Value
Base Case
48.72
USD
Undervaluation 92%
Valuation Multiples
Multiples Across Competitors
TTOO Competitors Multiples
T2 Biosystems Inc Competitors
T2 Biosystems Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
T2 Biosystems Inc
NASDAQ:TTOO
|
32.7m USD | 4.5 | -0.7 | -1.3 | -1.2 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
289.2B USD | 5.3 | 60 | 13 | 19.9 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
166.7B USD | 5.9 | 24.8 | 17.9 | 26.8 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
104.7B USD | 8 | 26.5 | 17.8 | 19.6 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
103.4B USD | 10.5 | 28.6 | 22.8 | 23.9 | |
| AU |
|
CSL Ltd
ASX:CSL
|
133.2B AUD | 6.2 | 35.6 | 21.6 | 26.7 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
80.7B USD | 2.9 | 166.8 | 6.7 | 8.8 | |
| US |
|
Moderna Inc
NASDAQ:MRNA
|
47.8B USD | 7 | -10.1 | -11 | -9.4 | |
| US |
|
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | 18.8 | -57.5 | -61.9 | -55.8 | |
| US |
|
Biogen Inc
NASDAQ:BIIB
|
31.7B USD | 3.3 | 27.1 | 13.9 | 17.4 | |
| KR |
|
Celltrion Inc
KRX:068270
|
39.2T KRW | 18 | 73.1 | 44.7 | 61.6 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
You don't have any saved screeners yet
